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Abstract
5,6-Dimethylxanthenone-4-acetic acid (DMXAA), a potent type I interferon (IFN) inducer, was evaluated as a
chemotherapeutic agent in mouse cancer models and proved to be well tolerated in human cancer clinical trials. Despite
its multiple biological functions, DMXAA has not been fully characterized for the potential application as a vaccine adjuvant.
In this report, we show that DMXAA does act as an adjuvant due to its unique property as a soluble innate immune
activator. Using OVA as a model antigen, DMXAA was demonstrated to improve on the antigen specific immune responses
and induce a preferential Th2 (Type-2) response. The adjuvant effect was directly dependent on the IRF3-mediated
production of type-I-interferon, but not IL-33. DMXAA could also enhance the immunogenicity of influenza split vaccine
which led to significant increase in protective responses against live influenza virus challenge in mice compared to split
vaccine alone. We propose that DMXAA can be used as an adjuvant that targets a specific innate immune signaling pathway
via IRF3 for potential applications including vaccines against influenza which requires a high safety profile.
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Introduction
DMXAA was developed as a vascular disruptive agent for use in
cancer therapy. Several clinical trials, including a recently
completed phase III clinical trial for non-small cell lung
carcinoma, have shown that DMXAA is safe and well-tolerated
in humans [1]. It is a cell-permeable small molecule which reduces
tumor load by inducing apoptosis in tumor vascular endothelium
thereby reducing blood flow to solid tumor [2]. Further
investigations into the properties of DMXAA have revealed that
it is a strongly immunogenic molecule. The anti-neoplastic
property of DMXAA is largely attributed to its induction of
TNFa which can be detected in the serum and tumor micro-
environment within hours of administration [3]. It can activate
several inflammatory cell signaling pathways, including extracel-
lular signal-regulated kinases 1 and 2, c-Jun N-terminal kinases,
and cytosolic nucleotide-binding oligomerization domain 1 and 2-
like receptors [4,5]. In addition, DMXAA is a strong inducer of
reactive oxygen species (ROS) [6]. The most striking immuno-
genic feature of DMXAA is its induction of immediate and
predominant type-I-IFN [7]. DMXAA resembles viral infections
and double stranded DNA (dsDNA) in the inflammatory signaling
events it triggers to induce type-I-IFN production [8]. It utilizes
the TBK1-IRF3 signaling pathway without the involvement of
Toll-like receptors (TLRs) or RNA helicases for its mechanism of
type-I-IFN induction. For the cell signaling events that are
upstream of TBK1 phosphorylation, DMXAA was shown to
initiate the translocation of the E3 ubiquitin ligase tripartite motif
56 (TRIM56) from the cytoplasm into intracellular punctate
structures where the Stimulator of Interferon Genes (STING) was
simultaneously recruited [9]. STING is an adaptor molecule that
is vital to the induction of type-I-IFN during viral infection [10]
and stimulation with cytosolic dsDNA [11] and the bacterial
second messenger product, cyclic diguanylate (c-di-GMP) [12].
DMXAA was recently demonstrated to require STING for the
production of IFN-b [13]. Due to its ability to induce strong type-
I-IFN, DMXAA was found to be an effective antiviral agent
against influenza [14,15].
In addition to the induction of pro-inflammatory cytokines,
DMXAA can induce the direct activation of antigen presenting
cells (APCs) such as macrophages and dendritic cells (DCs). In-vivo
administration of DMXAA induced maturation of DCs in
draining lymph node of tumor bearing mice within 24 h. This
was shortly followed by the increase of tumor antigen specific CD8
T cells and their migration to tumor sites due to chemokines such
as CCL2 and CXCL10 that were released by the activated APCs
[16]. Based on these immunogenic properties of DMXAA, we
hypothesize that DMXAA could function as an adjuvant. In this
report, we demonstrate in mouse models that DMXAA could
indeed promote the adaptive immune response in immunization
studies against influenza virus and be a potential adjuvant
candidate.
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Materials and Methods
Mice and immunizations
Ifnar-/- and Irf3-/- mice were of C57BL/6 background and IL-
33-/- mice were of BALB/c background. The development of
these animals was described elsewhere [17–19]. Wild-type (WT)
controls were purchased from CLEA, Japan. All animal experi-
ments were conducted in accordance with the guidelines of the
Animal Care and Use Committee of Research Institute for
Microbial Diseases and Immunology Frontier Research Center of
Osaka University, who specifically approved this study. All animal
experiments were performed to ameliorate suffering according to
the guideline of ASUDC of RIMD and IFREC of Osaka
university. Endotoxin-free chicken egg Ovalbumin (OVA) (Seika-
gaku Biobusiness) was mixed with various adjuvants, including
DMXAA (Sigma-Aldrich), aluminum hydroxide suspension (Sig-
ma Aldrich) and K-type CpG ODN 2006 (InvivoGen), in PBS
prior to immunization. DMXAA was dissolved in 5% NaHCO3
and was ensured endotoxin-free by analysis with LAL testing
(Lonza). In all immunization experiments, mice were injected
intradermally at the base of tail on days 0 and 14 and were bled on
day 21.
Generation and in-vitro stimulation of bone marrow
derived dendritic cells
In-vitro grown DCs were prepared by incubating red blood cells-
lysed bone marrow cells from WT and various knockout mice with
20 ng/ml of GM-CSF (Peprotech, NJ, USA) for 5 days as
previously described in [20]. On day 5, DCs were stimulated with
DMXAA, lipopolysaccharides (LPS) (Sigma Aldrich, MO, USA),
and Lipofectamine 2000 (Invitrogen, NY, USA) complexed c-di-
GMP (Biolog, Bremen, Germany) for 6 h before the supernatant
were collected and cytokines measured. The level of DC
maturation induced by the various stimuli were determined by
using flow cytometry to detect CD86 expression on CD11c+ cells
and presented as histogram plots.
Cytokine ELISA
TNFa was measured using the R&D DuoSetH ELISA
Development Systems (R&D Systems). IFNb was measured by
ELISA, using rat monoclonal [7F–D3] antibody to Interferon beta
(ab24324, Abcam) and rabbit polyclonal antibody to Interferon b
(#AB2215, Millipore) and finally with sheep antibody to rabbit
IgG (H&L-HRP; ab97095, Abcam). Standard curves were
generated using recombinant mouse IFNb (12400-1, Interferon
Source PBL). Results reported in the figures are averages of three
samples with errors displayed as standard deviations. Antibody
responses to OVA and SV were determined by ELISA where
plates were coated with OVA protein and SV respectively. The
OVA and SV specific antibodies were detected using goat anti-
mouse IgG, IgG1, IgG2a or IgG2c-HRP (Southern Biotech). The
relative antibody titers were determined directly from the standard
curve generated from positive serum by solving the regression line
equation. All ELISAs were developed with the KPL TMB
Microwell Peroxidase Substrate System (KPL).
Influenza virus infection and vaccination
Mice were immunized intradermally, at the base of the tail, on
days 0 and 14, with 100 mg DMXAA and 0.75 mg of New
Caledonia/20/1999 (H1N1), prepared as described [21]. On day
21, the immunized mice were anesthetized with ketamine before
they were intranasally infected with 16105 pfu of A/Puerto Rico/
8/34 (PR) (H1N1) virus. All efforts were made to reduce suffering
to the animal. Challenged mice were monitored daily for their
body weight loss and any signs of sickness. Mice that were in a
moribund condition or had loss more than 25% of body weight
were considered to have reached an experimental endpoint and
were humanely euthanized by cervical dislocation.
Statistical analysis
All data were reported as means 6 standard deviation. Students
t-test was used to compare significant differences between two
groups, whereas one-way analysis of variance with Bonferroni’s
post-test was used to compare differences among three or more
groups. Log-rank (Mantel-Cox) tests was used to analyze
significant difference between survival curves.
Results
DMXAA has adjuvant properties and induces preferential
type-2 response
To determine if the immunogenic property of DMXAA could
adjuvant vaccines, we utilized the OVA model antigen system
where C57BL/6 mice were immunized with OVA mixed with
DMXAA. We found that DMXAA could significantly augment
specific immune responses against OVA, as indicated by the
increase in serum anti-OVA total IgG (tIgG) titers compared to
OVA alone immunized group (Figure 1A). The adjuvant effect
was dependent on the dose of DMXAA. In addition, it was
observed to have noticeable but insignificant adjuvant effect at a
low dose of 10 mg. The immune response induced by the
combination of DMXAA and OVA was long-lasting and could
be detected as late as 150 days after the final immunization
(Figure 1B). To evaluate its efficacy, we compared DMXAA with
the established adjuvants, Alum and CpG DNA, which induce
predominantly TH2 and TH1 immune responses, respectively.
Mice immunized with OVA plus DMXAA (100 mg) generated
comparable anti-OVA tIgG titers as Alum (665 mg) and CpG
DNA (25 mg) adjuvanted groups (Figure 1C). DMXAA resembled
Alum in generating predominantly TH2 type responses as
indicated by the induction of higher IgG1 than IgG2c titers
(Figure 1D and 1E). In contrast, CpG DNA induced higher IgG2c
and lower IgG1 levels. We have also analyzed OVA specific T cell
responses by stimulating splenocytes of immunized mice with
whole OVA protein or its CD4 and CD8 epitopes followed by
measuring IFN-c secretion. No T-cell responses could be detected
in OVA plus Alum or DMXAA groups, whereas splenocytes from
the OVA plus CpG group responded with high IFN-c secretion in
the presence CD8 peptide and whole OVA protein (Figure 1F). In-
vivo depletion of CD4 T cells prior to immunization with OVA and
DMXAA completely abrogated the production of OVA-specific
antibodies (Figure 1G), suggesting that the generation of adaptive
immune responses by DMXAA was CD4 T cell-dependent. These
results indicate that DMXAA possesses immuno-stimulatory
properties that can function effectively as an adjuvant for vaccines.
Adjuvant effect of DMXAA is dependent on the type-I-
IFN response induced by IRF3 signaling
DMXAA has been shown to activate the TBK1-IRF-3 signaling
pathway to induce strong IFNb response from mouse embryonic
fibroblasts (MEFs), macrophages and dendritic cells [7]. A recent
study also reported that DMXAA could induce IL-33 up-
regulation through IRF3 dependent mechanism [22]. IL-33
promotes humoral immunity by triggering the release of TH2
cytokines such as IL-4, IL-5 and IL-13 from polarised naive T cells
[23]. Therefore we would like to determine if the adjuvant effect of
DMXAA requires IRF3-dependent type-I-IFN secretion and
DMXAA Works as a FLU Vaccine Adjuvant
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could the induction of preferential TH2 type response be due to its
up-regulation of IL-33.
To address this, OVA immunization studies were performed on
mice lacking IRF3 (Irf3-/-), IFNab receptor (Ifnar-/-) and IL-33 (Il-
33-/-). As observed in Figure 2A, the anti-OVA tIgG (Figure 2A)
titers from Irf3-/- and Ifnar-/- mice were significantly inhibited
compared to WT C57BL/6 mice. This indicates that the adjuvant
effect of DMXAA was strongly dependent on IRF3 mediated
transcription and responses mediated by type-I-IFN. In contrast to
Irf3-/- and Ifnar-/- mice, Il-33-/- mice showed comparable levels of
tIgG antibody response as WT BALB/c immunized mice
(Figure 2B). Moreover, the preference for the induction of IgG1
(Figure 2C) over IgG2a (Figure 2D) subtype as observed in WT
BALB/c mice remained the same in Il-33-/- mice. To further
support the dependence on IRF3 mediated type-I-IFN for
DMXAA adjuvant effect, bone marrow derived DCs from
Irf3-/-, Ifnar-/-and WT mice were stimulated with DMXAA
(Figure 2E–G). Cyclic diguanylate (c-di-GMP) is an IRF3-
dependent type-I-IFN inducer and was included as a control. As
observed in figure 2E, Irf3-/- DCs were unable to induce IFNb
response whilst Ifnar-/- DC responded with levels comparable to
WT DCs. Therefore indicating that the lack of DMXAA adjuvant
effect observed in Ifnar-/- mice was not due to the inability to
induce type-I-IFN but rather it was the inability to respond to it.
Although Irf3-/- and Ifnar-/- mice did not respond to the adjuvant
effect of DMXAA, it was found to be capable of inducing IL-6
(Figure 2F) and TNFa (Figure 2G) response from Irf3-/- and Ifnar-/-
DCs. In addition, the DC maturation effect of DMXAA was still
present in Irf3-/- and Ifnar-/- DCs in the same order of magnitude
as WT DCs (Figure 2H). These data suggest that other stimulatory
pathways of DMXAA remained intact in Irf3-/- mice but they did
not play a role in the adjuvant effects of DMXAA. Collectively, we
demonstrate that the adjuvant effect of DMXAA is directly
dependent on IRF3 mediated type-I-IFN induction and that the
reported IL-33 up-regulation by DMXAA is not involved in
raising immunogenicity of the vaccine or the skewing towards Th2
type response.
DMXAA is a potent adjuvant for influenza split virus
vaccine and enhances protection against influenza
challenge
In our previous report, we have demonstrated that in contrast to
influenza whole virus vaccine (WV), split vaccine (SV) was unable
to induce type-I-IFN production from plasmacytoid DCs [21].
This was due to the lack of RNA content in the SV preparation
required to trigger TLR7 activation. As a result, SV immuniza-
tions were less protective against lethal influenza challenge as
compared to WV immunizations. Hence, we would like to
Figure 1. DMXAA acts as a potent adjuvant. (A) Anti-OVA tIgG titers of C57BL/6 mice immunized with 100 mg OVA plus the indicated doses of
DMXAA (mg). (B) Anti-OVA tIgG titers of C57BL/6 mice 21 days and 150 days after immunization with 100 mg OVA and 100 mg DMXAA. (C–E) C57BL/6
mice were immunized twice i.d. with 100 mg OVA plus DMXAA (100 mg), Alum (665 mg) or CpG DNA (25 mg) and the induction of (C) tIgG, (D) IgG1
and (E) IgG2c antibody responses against OVA were assessed. (F) IFN-c secretion from splenocytes of immunized mice that were stimulated for 48 h
with CD4 and CD8 OVA peptides and whole OVA protein. (G) Anti-OVA tIgG titers of C57BL/6 mice injected i.v. with 200 mg anti-CD4 (GK1.5)
antibodies prior to immunization with 100 mg OVA and 100 mg DMXAA. Results presented are representatives of three separate experiments. *,0.05,
** P,0.01, *** P,0.001 by Students t-test when comparing between two groups and one-way ANOVA with Bonferroni’s post-test when comparing
three or more groups.
doi:10.1371/journal.pone.0060038.g001
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determine if the type-I-IFN dependent adjuvant effect of DMXAA
could adjuvant SV and immunized mice from live flu challenges.
C57BL/6 WT mice were immunized intradermally with SV
prepared from New Caledonia/20/1999 (H1N1) and mixed with
DMXAA. We found that SV plus DMXAA induced higher tIgG
antibody responses than SV alone immunizations (Figure 3A).
Similar to OVA immunization studies, the adjuvant effect of
DMXAA induced higher IgG1 than IgG2c titers to SV (Figure 3B
Figure 2. Adjuvant effects of DMXAA require type-I-IFN responses induced by IRF3 activation. Anti-OVA (A) tIgG antibody responses of
WT C57BL/6, Ifnar-/- and Irf3-/- mice immunized twice i.d. with 10 mg OVA plus 100 mg DMXAA. (B) tIgG, (C) IgG1 and (D) IgG2a antibody titers against
OVA in WT BALB/c and Il-33-/- mice immunized twice i.d. with 10 mg OVA plus 100 mg DMXAA. Results presented are pooled titers from two separate
experiments. In-vitro cultured DCs derived from WT, Ifnar-/- and Irf3-/- mice were stimulated with DMXAA (2.5 mg/ml), LPS (1 mg/ml) or lipofectamine
complexed c-di-GMP (10 mg/ml) for 6 h before the supernatant were collected and analysed for (E) IFNb, (F) IL-6 and (G) TNFa secretion and CD11c+
cells were analysed for CD86 expression (H). Results presented are average of triplicate conditions 6 SD and are representative of three separate
experiments. *** P,0.001 one-way ANOVA with Bonferroni’s post-test.
doi:10.1371/journal.pone.0060038.g002
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and 3C). Next, we challenged the immunized mice with a high
dose of A/Puerto Rico/8/34 (PR) (H1N1). As seen in Figure 3D,
naive mice were quick to succumb to the selected dose of live
influenza challenge whilst SV alone immunized mice were offered
low level protection (Figure 3A). Although SV alone immuniza-
tions had low antibody titers, it was found to be mildly
immunogenic and capable of inducing detectable CXCL10 and
Anti-HA BALF IgA production [21] that may account for the low
level of protective response observed. In contrast, mice immunized
with SV plus DMXAA had significantly higher survival rates than
naive mice and mice immunized with SV alone (Figure 3D). 11
out of 12 mice that were immunized with SV + DMXAA survived
the lethal challenge compared to the 3 out of 12 SV alone group.
It was also observable from the rate of weight-loss that SV plus
DMXAA immunized mice had a lesser degree of disease-induced
morbidity and were able to recover from the infection at a faster
rate than control groups (Figure 3E). To exclude the possible role
of DMXAA-induced innate immune responses in the protection
against lethal challenge, the survival rate of mice injected with
DMXAA alone without SV was determined and found to be
similar as naı¨ve mice (Figure 3D). Therefore the protective
response observed in SV + DMXAA immunized group was due to
the adaptive response generated from the immunization and not
the innate immune response triggered by DMXAA. These results
demonstrate that DMXAA is an efficacious adjuvant for SV
vaccine.
Discussion
A large cohort Phase III clinical trial of DMXAA on patients
with non-small cell lung carcinoma was recently halted due to
inefficacy although it was shown to be well tolerated [1]. As
opposed to an earlier successful Phase II clinical trial [24], the
Phase III trial showed no overall survival between DMXAA and
placebo treated groups. The researchers conducting the clinical
trial reasoned that a smaller sample size in the phase II trial
overestimated the efficacy of DMXAA. The future of DMXAA as
a vascular disruptive agent for cancer therapy is therefore
uncertain. In this report, we have demonstrated that the
immunogenic properties of DMXAA could be harnessed to
adjuvant vaccines with its acceptable safety profile. A local low-
dose of DMXAA was capable of adjuvanting vaccines with efficacy
that was comparable to the well-studied adjuvants, Alum and
CpG. The adjuvant activity was observed using amounts as low as
10 mg per mouse, which was a smaller dose than the 30 mg/kg
required for the vascular disruptive effect [25]. When extrapolated
to human use, the lower dose required for the adjuvant activity
serves to promote DMXAA as a candidate for vaccine adjuvant.
Despite the activation of several distinct inflammatory signaling
pathways, we narrowed the immune activity responsible for the
adjuvant effect of DMXAA to the IRF3 mediated activation of
type-I-IFN. This is surprising as DMXAA induced biased TH2
response while type-I-IFN is commonly associated with the
Figure 3. Adjuvant effect of DMXAA can improve potency of influenza SV vaccine and protect mice from a lethal challenge. C57BL/6
mice were immunized twice i.d. with 0.75 mg SV and 100 mg DMXAA, and their sera were assessed for anti-SV (A) tIgG, (B) IgG1 and (C) IgG2c
antibodies. ** P,0.01 by Students t-test. Results presented are pooled from two separate experiments. (D) C57BL/6 mice that had received two i.d.
injections of PBS (open square), 100 mg DMXAA alone (open circle), 0.75 mg SV alone (grey-filled circle) or SV plus DMXAA (black filled circle) were
challenged with a lethal dose of A/Puerto Rico/8/34 (PR) (H1N1) 7 days after the final immunization (n = 6 mice per experimental group). Results
presented are pooled from two separate experiments. Survival rates were recorded daily and statistical analyses were performed using the log-rank
(Mantel-Cox) test where ** and *** denotes p,0.01 and p,0.001 respectively (E) The rate of weight-loss by the challenged mice were monitored and
presented as an average percentage of the initial base weight 6 standard error. * denotes p,0.05 vs SV alone by Student’s T-test.
doi:10.1371/journal.pone.0060038.g003
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generation of TH1 response in-vivo [26]. The recent study reporting
that DMXAA could induce IL-33 up-regulation through IRF3
dependent mechanism made us question if this could be the reason
for the unusual observation [22]. However, immunization studies
performed on Il-33-/- mice confirmed that IL-33 was not involved
in the adjuvant effect of DMXAA or its skewing towards TH2
response. We have recently reported that Alum mediates
enhancement of TH2 response through the DNA sensing pathway
triggered by the release of dsDNA from dying host cells [18].
However, we found that DMXAA did not induce significant
increase in free dsDNA in the peritoneal lavage of mice when
injected intraperitoneally as opposed to Alum (data not shown).
Therefore the mechanism through which DMXAA induced
preferential TH2 type responses remains elusive and requires
further investigation. It is possible that the production of IL-6 by
DMXAA to be involved as it has been known to inhibit TH1
polarization by activating NFAT, c-maf and SOCS-1 [27,28] and
induce the humoral immunity promoting cytokine, IL-21.
The revealing of DMXAA adjuvant property suggests that it
could adjuvant tumor associated antigens and activate the
adaptive immune system against cancer cells as part of its anti-
tumor response. So far, there are no reports on DMXAA raising
humoral immunity against tumor cells with its TH2 enhancing
capability. However, there is evidence which suggests that
DMXAA could act as a cancer vaccine adjuvant. For example,
it was demonstrated that the administration of DMXAA in tumor
bearing mice could increase the number of circulating specific
CD8 T-cells [16]. It was also shown to have a positive influence in
a separate study which investigated if the anti-cancer property of
systemic high-dose DMXAA could work in combination with the
adaptive immune response generated by DNA vaccine to protect
mice against tumor challenges [29].
In summary, results from this report have shown that DMXAA
is capable of functioning as an adjuvant with a defined mechanism
that acts specifically on the IRF3 dependent induction of type-I-
IFN. DMXAA has already been investigated for applications in
antiviral [15] and anti-bacterial [30] therapies and here we
demonstrate that it is capable of adjuvanting vaccines as well.
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